Research & Development

Celularity and GX Acquisition announce merger agreement to create publicly listed leader in allogeneic cellular therapy

Celularity, a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and GX Acquisition Corp. (Nasdaq: GXGX), a special purpose acquisition company, today announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity.

Affinivax secures $226m in Series C financing to boost MAPS vaccine pipeline

Clinical-stage biopharmaceutical company Affinivax has secured $226m in Series C financing to advance the development of new vaccines with its multiple antigen presenting system (MAPS) platform.

Bayer and CureVac collaborate on Covid-19 vaccine candidate

German pharmaceutical and life sciences company Bayer has entered into a collaboration and services agreement with biopharmaceutical firm CureVac on Covid-19 vaccine called CVnCoV.

Xencor, MD Anderson enter collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of cancer

Xencor and The University of Texas MD Anderson Cancer Center announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.

Angelini Pharma to buy Arvelle Therapeutics for up to $960m

Angelini Pharma has agreed to acquire Swiss biopharmaceutical company Arvelle Therapeutics in a deal valued up to $960m.

Moderna in talks with South Korea to supply 40 million doses of Covid-19 vaccine

Biotechnology company Moderna is negotiating with the South Korean government to potentially provide 40 million or more doses of its vaccine against Covid-19.

Aurobindo, COVAXX sign deal to develop Covid-19 vaccine UB-612

Aurobindo Pharma has signed an exclusive license agreement with US-based COVAXX to develop the latter’s UB-612 multitope peptide-based vaccine to fight Covid-19.

Hyundai Bioscience develops injection drug for potential treatment of severe cases of Covid-19

Hyundai Bioscience announced that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of Covid-19.

Servier to buy Agios’ oncology business for up to $2bn

Pharmaceutical company Servier has agreed to acquire oncology business from Agios Pharmaceuticals for up to $2bn.